2024
Lemierre syndrome with pulmonary empyema caused by Prevotella intermedia
Simsek B, Zhang R, Morton C, Villanueva M. Lemierre syndrome with pulmonary empyema caused by Prevotella intermedia. BMJ Case Reports 2024, 17: e258158. PMID: 38490705, PMCID: PMC10946344, DOI: 10.1136/bcr-2023-258158.Peer-Reviewed Original ResearchConceptsLemierre's syndromeMultiple cavitary lung lesionsCavitary lung lesionsChest tube placementLoculated pleural effusionPrevotella intermediaAntimicrobial therapyRare causePleural effusionPulmonary empyemaTube placementRare diseaseLung lesionsHealthy menSyndromeLemierreEmpyemaAbscessEffusionTherapyLesions
2023
Brief Report: Increasing Prevalence of Ground-Glass Nodules and Semisolid Lung Lesions on Outpatient Chest Computed Tomography Scans
Woodard G, Udelsman B, Prince S, Blasberg J, Dhanasopon A, Gange C, Traube L, Mase V, Boffa D, Detterbeck F, Bader A. Brief Report: Increasing Prevalence of Ground-Glass Nodules and Semisolid Lung Lesions on Outpatient Chest Computed Tomography Scans. JTO Clinical And Research Reports 2023, 4: 100583. PMID: 38074773, PMCID: PMC10709040, DOI: 10.1016/j.jtocrr.2023.100583.Peer-Reviewed Original ResearchGround-glass nodulesChest CT scanCT scanLung lesionsHealth systemLarge academic health systemAcademic health systemCross-sectional imagingRadiographic findingsPhysician consultationChest CTDatabase reviewTomography scanRadiographic lesionsAge groupsLesionsStudy periodLung nodulesOutpatient CTRadiology reportsAdult chestCTScansChestNodulesA pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial
Malarkey M, Toscano A, Bagheri M, Solomon J, Machado L, LoRusso P, Chen A, Folio L, Goncalves P. A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial. Heliyon 2023, 9: e18680. PMID: 37593628, PMCID: PMC10428039, DOI: 10.1016/j.heliyon.2023.e18680.Peer-Reviewed Original ResearchACC patientsClinical trialsTarget lesionsSolid tumorsPhase II clinical trialPilot studyPhase 2 trialResponse Evaluation CriteriaSalivary gland cancerRare salivary gland cancerSystemic therapy efficacyStable diseaseGland cancerLung lesionsComputed tomography (CT) examsCystic carcinomaTherapy responseBlinded observersTomography examsTherapy efficacyLesionsInter-observer variationPatientsAppropriate evaluationTrialsA Multiclass Radiomics Method–Based WHO Severity Scale for Improving COVID-19 Patient Assessment and Disease Characterization From CT Scans
Henao J, Depotter A, Bower D, Bajercius H, Todorova P, Saint-James H, de Mortanges A, Barroso M, He J, Yang J, You C, Staib L, Gange C, Ledda R, Caminiti C, Silva M, Cortopassi I, Dela Cruz C, Hautz W, Bonel H, Sverzellati N, Duncan J, Reyes M, Poellinger A. A Multiclass Radiomics Method–Based WHO Severity Scale for Improving COVID-19 Patient Assessment and Disease Characterization From CT Scans. Investigative Radiology 2023, 58: 882-893. PMID: 37493348, PMCID: PMC10662611, DOI: 10.1097/rli.0000000000001005.Peer-Reviewed Original ResearchConceptsCOVID-19 positive patientsClinical Progression ScaleLung lesionsLesion modelDisease severityGround-glass opacitiesCOVID-19 patientsRadiologist assessmentExpert thoracic radiologistsMulticenter cohortPleural effusionDisease extentRetrospective studyDevelopment cohortPatient assessmentTomography scanCT scanSeverity ScalePatient's diseaseTissue lesionsThoracic radiologistsLesionsPatientsRadiomics modelRadiomic featuresComparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas
Woodard G, Ding V, Cho C, Brand N, Kratz J, Jones K, Jablons D. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Lung Cancer 2023, 180: 107211. PMID: 37121213, PMCID: PMC10900430, DOI: 10.1016/j.lungcan.2023.107211.Peer-Reviewed Original ResearchConceptsInvasive portionDriver mutationsSolid adenocarcinomaLung cancer driver mutationsNext-generation sequencingWarrants further studyLobar resectionClinical characteristicsSurgical databaseAsian patientsInvasive cancerPoor prognosisLung cancerLung lesionsInvasive componentInvasive solid tumorsNormal lungLepidicStage IPromising biomarkerSolid tumorsCancer developmentSame time periodGenes SPP1Gene expression
2022
Chronic lung lesions in COVID-19 survivors: predictive clinical model
Carvalho C, Chate R, Sawamura M, Garcia M, Lamas C, Cardenas D, Lima D, Scudeller P, Salge J, Nomura C, Gutierrez M, Araújo A, Segurado A, Montal A, Miethke-Morais A, Levin A, Perondi B, Guedes B, Carmo C, Lázari C, Antonio C, Tanaka C, Leite C, Gomes C, Utiyama E, Burdmann E, Bonfá E, Kallas E, Sabino E, Miguel E, Pinna F, Kawano F, Busatto G, Cerri G, Fonseca G, Souza H, Marcilio I, Rios I, Hallak J, Krieger J, Ferreira J, Marchini J, Oliveira L, Harima L, Batisttella L, Yu L, Castro L, Rocha M, Magri M, Mancini M, de Jesus M, Corrêa M, Francisco M, Rossi M, Silva M, Imamura M, Oliveira M, Gouveia N, Forlenza O, Lotufo P, Bento R, Nitrini R, Damiano R, Chammas R, Francisco R, Fusco S, Barros-Filho T, Mauad T, Guimarães T, Avelino-Silva T, Filho W. Chronic lung lesions in COVID-19 survivors: predictive clinical model. BMJ Open 2022, 12: e059110. PMID: 35697456, PMCID: PMC9195157, DOI: 10.1136/bmjopen-2021-059110.Peer-Reviewed Original ResearchConceptsChest X-rayPredictive clinical modelCOVID-19 survivorsLung lesionsClinical modelLung lesion detectionMMRC scaleChest CTMedical Research Council dyspnoea scaleSARS-CoV-2-infected patientsSARS-CoV-2 infectionCOVID-19 sequelaeSignificant pulmonary abnormalitiesProspective cohort studyGround-glass opacitiesCOVID-19 infectionChronic lung lesionsLesion detectionDyspnoea scalePulmonary involvementTraction bronchiectasisCohort studyCXR findingsHospital dischargePulmonary function
2021
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
Xie Y, de Jager V, Chen R, Dodd L, Paripati P, Via L, Follmann D, Wang J, Lumbard K, Lahouar S, Malherbe S, Andrews J, Yu X, Goldfeder L, Cai Y, Arora K, Loxton A, Vanker N, Duvenhage M, Winter J, Song T, Walzl G, Diacon A, Barry C. Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Science Translational Medicine 2021, 13 PMID: 33536283, PMCID: PMC11135015, DOI: 10.1126/scitranslmed.abd7618.Peer-Reviewed Original ResearchConceptsPET/CT imagingPET/CTDrug treatmentCT imagingDrug combinationsD-glucose positron emission tomographyRecent phase 3 clinical trialsPhase 3 clinical trialsEarly bactericidal activity studyDrug combination activitySputum bacterial loadFirst-line chemotherapyPhase 3 trialHigh FDG uptakeLung lesion volumeActivity of pyrazinamideNew TB drugsPositron emission tomographyExperimental drug treatmentDrug regimensRadiological responseClinical outcomesFDG uptakeLung lesionsTB drugs
2019
- Lung lesionsNon-small cell carcinomaNon-hematopoietic tumorsMediastinal lymph nodesFine-needle aspirationLymph nodesCell carcinomaHematopoietic lesionsNeedle aspirationCytomorphologic featuresDiagnostic pitfallsMolecular testingLesionsAppropriate specimen triageSpecimen triageSite evaluationBiopsyCarcinomaLungTumorsTriage
Utility of Fetal Cardiac Axis and Cardiac Position Assessment in Predicting Neonatal Respiratory Morbidity in Fetal Congenital Lung Lesions
Tuzovic L, Copel JA, Stitelman DH, Levit O, Bahtiyar MO. Utility of Fetal Cardiac Axis and Cardiac Position Assessment in Predicting Neonatal Respiratory Morbidity in Fetal Congenital Lung Lesions. Journal Of Ultrasound In Medicine 2019, 38: 2361-2372. PMID: 30653685, DOI: 10.1002/jum.14931.Peer-Reviewed Original ResearchConceptsAbnormal cardiac axisNegative predictive valueFetal cardiac axisNeonatal respiratory morbidityRespiratory morbidityCongenital lung lesionsCardiac positionPositive predictive valuePredictive valueCardiac axisLung lesionsHigh negative predictive valueSevere respiratory morbidityRetrospective cohort studyRight-sided lesionsNormal cardiac axisCohort studyWeeks' gestationMorbidityCP assessmentWeeksDiagnostic performanceLesionsPatientsGestation
2018
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Adam LC, Raja J, Ludwig JM, Adeniran A, Gettinger SN, Kim HS. Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy. Journal For ImmunoTherapy Of Cancer 2018, 6: 147. PMID: 30541627, PMCID: PMC6292083, DOI: 10.1186/s40425-018-0468-x.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerMetastatic diseaseNodal metastasisLung cancerMetastatic non-small cell lung cancerDurable complete responseLymph nodal metastasisMalignant pericardial effusionCervical lymph nodesPD-L1 expressionSquamous cell cancerImmune checkpoint immunotherapyLong-term effectivenessCombination immunotherapyCheckpoint inhibitorsPericardial effusionCheckpoint immunotherapyComplete responseLymph nodesCell cancerFemale smokersLung lesionsResistant metastasesConventional chemotherapyA Young Man With Hemoptysis and Cavitary Lung Lesions
Brady VA, Zinchuk AV, Siegel MD, Possick JD. A Young Man With Hemoptysis and Cavitary Lung Lesions. CHEST Journal 2018, 153: e85-e88. PMID: 29626974, PMCID: PMC6026285, DOI: 10.1016/j.chest.2017.09.018.Peer-Reviewed Case Reports and Technical NotesConceptsBacillus Calmette-Guérin (BCG) vaccineCavitary lung lesionsPrior cigarette smokingCalmette-Guérin vaccineHistory of alcoholIntermittent hemoptysisNight sweatsCigarette smokingMusculoskeletal symptomsLung lesionsMild fatigueDrug useWeight lossHemoptysisYoung menMenDyspneaRashMedicationsSmokingFeverVaccineLesionsSymptomsMonths
2017
Congenital Cystic Lung Lesions
Hardee S, Tuzovic L, Silva CT, Cowles RA, Copel J, Morotti RA. Congenital Cystic Lung Lesions. Pediatric And Developmental Pathology 2017, 20: 403-410. PMID: 28812458, DOI: 10.1177/1093526617698604.Peer-Reviewed Original ResearchConceptsCongenital cystic lung lesionsCongenital pulmonary airway malformationCystic lung lesionsBronchopulmonary sequestrationLung lesionsPrenatal ultrasoundSingle tertiary care centerPulmonary airway malformationTertiary care centerFinal pathologic diagnosisCorrelate imagingCPAM lesionsAirway malformationExcellent prognosisPostnatal imagingRetrospective reviewPathological findingsPathology databaseRare pathologySurgical interventionBronchial atresiaPrenatal coursePathologic diagnosisPathology examinationCare centerIL-27 LIMITS TYPE 2 IMMUNOPATHOLOGY FOLLOWING PARAINFLUENZA VIRUS INFECTION
Muallem G, Wagage S, Sun Y, DeLong JH, Valenzuela A, Christian DA, Pritchard G, Fang Q, Buza EL, Jain D, Elloso MM, López CB, Hunter CA. IL-27 LIMITS TYPE 2 IMMUNOPATHOLOGY FOLLOWING PARAINFLUENZA VIRUS INFECTION. PLOS Pathogens 2017, 13: e1006173. PMID: 28129374, PMCID: PMC5305264, DOI: 10.1371/journal.ppat.1006173.Peer-Reviewed Original ResearchConceptsParainfluenza virus infectionTh2 responsesIL-27Control miceT cellsVirus infectionParamyxovirus infectionDisease severityWeight lossPathogenic Th2 responsesQuality of CD4Type 2 immunopathologyT-cell depletionT cell responsesSevere lung lesionsPopulation of IFNParainfluenza infectionsPulmonary eosinophilsRespiratory paramyxovirusesT helperCell depletionLung lesionsImmune responseLimit pathologyCD4
2016
CONGENITAL CYSTIC LUNG LESIONS: EVOLUTION FROM IN-UTERO TO PATHOLOGY DIAGNOSIS - A MULTIDISCIPLINARY APPROACH
Hardee S, Tuzovic L, Silva C, Cowles R, Copel J, Morotti R. CONGENITAL CYSTIC LUNG LESIONS: EVOLUTION FROM IN-UTERO TO PATHOLOGY DIAGNOSIS - A MULTIDISCIPLINARY APPROACH. Pediatric And Developmental Pathology 2016 DOI: 10.2350/16-05-1815-oa.1.Peer-Reviewed Original ResearchCongenital cystic lung lesionsCongenital pulmonary airway malformationBronchopulmonary sequestrationPrenatal ultrasoundSingle tertiary care centerCystic lung lesionsPulmonary airway malformationTertiary care centerFinal pathologic diagnosisCorrelate imagingCPAM lesionsAirway malformationExcellent prognosisPathological findingsPostnatal imagingRetrospective reviewPathology databaseSurgical interventionRare pathologyBronchial atresiaLung lesionsPathologic diagnosisPrenatal coursePathology examinationCare center
2015
Pulmonary imaging using respiratory motion compensated simultaneous PET/MR
Dutta J, Huang C, Li Q, Fakhri G. Pulmonary imaging using respiratory motion compensated simultaneous PET/MR. Medical Physics 2015, 42: 4227-4240. PMID: 26133621, PMCID: PMC4474958, DOI: 10.1118/1.4921616.Peer-Reviewed Original ResearchConceptsRespiratory motionContrast-to-noise ratioClinical patient studiesPulse sequenceHigh-intensity featuresXCAT studyLow proton densityXCAT simulationPatient studiesXCAT phantomAttenuation mapBiograph mMRComplete data acquisitionSimultaneous PET/MRNonrigid registrationPET/MR scannersPET/magnetic resonanceMagnetic susceptibilityProton densityQuantitative accuracyRelaxation timePulmonary imagingLung lesionsBlurring artifactsDeformation field
2013
Enhancing clinical utility of respiratory-gated PET/CT using patient respiratory trace classification
Bowen S, Pierce L, Alessio A, Liu C, Kinahan P. Enhancing clinical utility of respiratory-gated PET/CT using patient respiratory trace classification. 2011 IEEE Nuclear Science Symposium Conference Record 2013, 2881-2885. DOI: 10.1109/nssmic.2012.6551657.Peer-Reviewed Original ResearchLesion locationDiagnostic CTMaximum standardized uptake valueUpper lung lesionSelection of patientsPatient selection guidelinesStandardized uptake valueLiver cancer patientsPET/CTPET/CT examsLower lungPatient groupCancer patientsLung lesionsPET parametersClinical utilityLiver lesionsResponse assessmentPatientsPET imagesUptake valueCT examsLinear associationAbdominal displacementCT
2003
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. Journal Of Clinical Oncology 2003, 21: 2574-82. PMID: 12829678, DOI: 10.1200/jco.2003.01.144.Peer-Reviewed Original ResearchConceptsTumor sizeTumor responseLung tumorsSerial measurementsComputed tomographyWorld Health Organization criteriaResponse Evaluation CriteriaLung tumor sizeProgressive diseaseWHO criteriaOrganization criteriaLung lesionsSolid malignanciesStudy groupCT scanSolid tumorsIrregular tumorTumorsThoracic radiologistsResponse criteriaSignificant differencesPatientsInterobserver measurementsUnidimensional measurementBD measurements
2002
PULMONARY TOXICITY OF SIMULATED LUNAR AND MARTIAN DUSTS IN MICE: I. HISTOPATHOLOGY 7 AND 90 DAYS AFTER INTRATRACHEAL INSTILLATION
Lam CW, James JT, McCluskey R, Cowper S, Balis J, Muro-Cacho C. PULMONARY TOXICITY OF SIMULATED LUNAR AND MARTIAN DUSTS IN MICE: I. HISTOPATHOLOGY 7 AND 90 DAYS AFTER INTRATRACHEAL INSTILLATION. Inhalation Toxicology 2002, 14: 901-916. PMID: 12396402, DOI: 10.1080/08958370290084683.Peer-Reviewed Original ResearchConceptsParticle-laden macrophagesPeribronchiolar inflammationLung lesionsPulmonary toxicityChronic pulmonary inflammationChronic inflammatory lesionsEvidence of inflammationAcute inflammatory responseNumber of macrophagesFocal alveolitisLung injurySeptal thickeningPulmonary inflammationInflammatory lesionsMild fibrosisExamination 7Chronic mildInflammatory responseAlveolitisFibrosisInflammationLungOverall severityMSS groupMice
2000
Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells
Yano S, Shinohara H, Herbst R, Kuniyasu H, Bucana C, Ellis L, Fidler I. Production of Experimental Malignant Pleural Effusions Is Dependent on Invasion of the Pleura and Expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by Human Lung Cancer Cells. American Journal Of Pathology 2000, 157: 1893-1903. PMID: 11106562, PMCID: PMC1885766, DOI: 10.1016/s0002-9440(10)64828-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsCapillary PermeabilityCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCytokinesEndothelial Growth FactorsHumansLungLung NeoplasmsLymphokinesMatrix MetalloproteinasesMiceMice, NudeNeoplasm InvasivenessNeoplasm TransplantationOligonucleotides, AntisensePleuraPleural EffusionTissue Inhibitor of MetalloproteinasesTransfectionTumor Cells, CulturedUrokinase-Type Plasminogen ActivatorVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsTreatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clinical Cancer Research 2000, 6: 957-65. PMID: 10741721.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAngiogenesis InhibitorsAnimalsCapillary PermeabilityCell DivisionCell LineEndothelial Growth FactorsEndothelium, VascularGene Expression RegulationHumansImmunohistochemistryIn Situ HybridizationLung NeoplasmsLymphokinesMaleMiceMice, Inbred BALB CMice, NudeNeoplasm TransplantationNeovascularization, PathologicPhosphorylationPhthalazinesPleural Effusion, MalignantPyridinesReceptor Protein-Tyrosine KinasesReceptors, Growth FactorReceptors, Vascular Endothelial Growth FactorTransplantation, HeterologousTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsMalignant pleural effusionReceptor tyrosine kinase inhibitorsPleural effusionPTK 787Human dermal microvascular endothelial cellsTyrosine kinase inhibitorsPC14PE6 cellsDermal microvascular endothelial cellsMicrovascular endothelial cellsVEGF/VPFOral treatmentLung lesionsGrowth factor receptor tyrosine kinase inhibitorsAdvanced human lung cancerPlatelet-derived growth factor receptor tyrosine kinase inhibitorVEGF/VPF proteinEndothelial cellsKinase inhibitorsVascular endothelial growth factor/vascular permeability factorHuman lung cancerNude mouse modelHuman lung adenocarcinomaHuman lung adenocarcinoma cellsVascular permeability factorHuman lung carcinoma cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply